Glioblastoma Prognosis
Glioblastoma carries a grave prognosis with median overall survival of approximately 12-20 months and 5-year survival rates below 10%, even with maximal treatment. 1, 2
Survival Expectations
The prognosis for glioblastoma patients depends heavily on treatment received and molecular characteristics:
- Standard treatment (surgery + radiotherapy + temozolomide): Median survival 12-15 months 2
- With tumor-treating fields added: Median survival extends to approximately 20.9 months 2
- Population-based real-world data: Median survival 12.8 months (1.07 years) 3
- Long-term survival rates:
Critical Prognostic Factors
The strongest independent predictors of survival are:
Molecular Markers
- MGMT promoter methylation status: The single most powerful predictor of survival 1, 3. Patients with methylated MGMT promoters have substantially longer survival and derive greater benefit from temozolomide chemotherapy.
- IDH mutation status: IDH-mutant tumors (now classified as IDH-mutant astrocytoma, WHO grade 4) have significantly better prognosis than IDH-wild-type glioblastoma 1
Clinical Factors
- Age: Younger patients have markedly better outcomes; age >60 years is associated with significantly worse prognosis 6, 3, 7
- Performance status: Karnofsky Performance Status (KPS) ≥70 predicts better survival 1, 5
- Extent of resection: Gross total resection of enhancing tumor is associated with longer survival compared to subtotal resection or biopsy 1, 3
- Tumor location: Unilateral, non-central location with fewer lobes involved predicts better outcomes 3
- Comorbidities: Absence of significant comorbidities improves prognosis 3
Recurrent Disease
Recurrent glioblastoma has an extremely poor prognosis with median survival of only 6 months 2. However, recent data suggests salvage chemotherapy combined with anti-angiogenic drugs (particularly apatinib) may extend survival to 33 months versus 19 months with chemotherapy alone 4.
Common Pitfalls
- Approximately half of patients have KPS ≤70 at diagnosis, limiting treatment options 5
- Only about half of patients achieve total resection due to tumor location and infiltrative nature 5
- Median age at diagnosis is 68 years, placing many patients in unfavorable prognostic categories 5
- The tumor's rapid growth rate often limits the window for optimal intervention 5
Treatment Impact on Prognosis
The addition of temozolomide to radiotherapy has improved outcomes, but the benefit is largely limited to patients with MGMT promoter-methylated tumors 1. For elderly patients (≥60 years) with unmethylated MGMT promoters, hypofractionated radiotherapy alone may be appropriate, while those with methylated tumors may receive temozolomide alone 1.
Despite aggressive multimodal treatment including surgery, radiotherapy, and chemotherapy, glioblastoma remains universally fatal in the vast majority of patients, with survival measured in months rather than years 2, 3.